⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for recurrent adult diffuse large cell lymphoma

Every month we try and update this database with for recurrent adult diffuse large cell lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP)NCT00450385
Lymphoma
Rituximab
Cyclophosphamid...
Doxorubicin
Prednisone
Vincristine
18 Years - 120 YearsUniversity of Miami
Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell LymphomaNCT00392496
Adult Diffuse L...
Recurrent Adult...
Stage IV Adult ...
sunitinib malat...
18 Years - National Cancer Institute (NCI)
Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's LymphomaNCT00019708
Extranodal Marg...
Nodal Marginal ...
Non-Hodgkin Lym...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Margi...
Recurrent Small...
Splenic Margina...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Unspecified Adu...
tanespimycin
19 Years - National Cancer Institute (NCI)
Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell TransplantationNCT00003056
Leukemia
Lymphoma
Graft Versus Ho...
cyclosporine
cyclosporine an...
18 Years - 55 YearsTakeda
Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative DiseaseNCT00176475
Leukemia
Lymphoma
Multiple Myelom...
rituximab
therapeutic all...
18 Years - Rutgers, The State University of New Jersey
Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell TransplantationNCT00003143
Lymphoma
Amifostine
DHAP
18 Years - Jonsson Comprehensive Cancer Center
Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's LymphomaNCT00244946
Lymphoma
therapeutic aut...
carmustine
cytarabine
etoposide
melphalan
peripheral bloo...
15 Years - 70 YearsBarbara Ann Karmanos Cancer Institute
Memory-enriched CAR-T Cells Immunotherapy for B Cell LymphomaNCT02652910
Recurrent Adult...
Recurrent Folli...
Recurrent Mantl...
Stage III Adult...
Stage III Folli...
Stage III Mantl...
Stage IV Adult ...
Stage IV Follic...
Stage IV Mantle...
CD19.CAR-T cell...
18 Years - 70 YearsXinqiao Hospital of Chongqing
Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin LymphomaNCT00538187
Adult Non-Hodgk...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
obatoclax mesyl...
bortezomib
laboratory biom...
pharmacological...
18 Years - National Cancer Institute (NCI)
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaNCT00119392
B-cell Chronic ...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Splenic Margina...
Waldenström Mac...
rituximab
cyclosporine
fludarabine pho...
mycophenolate m...
yttrium Y 90 ib...
peripheral bloo...
allogeneic hema...
total-body irra...
18 Years - Fred Hutchinson Cancer Center
Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin LymphomaNCT00863369
Lymphoma
rituximab
bortezomib
gemcitabine hyd...
questionnaire a...
18 Years - City of Hope Medical Center
Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's LymphomaNCT00017381
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Extranodal Marg...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Stage I Adult D...
Stage I Adult D...
Stage I Grade 1...
Stage I Grade 2...
Stage I Grade 3...
Stage I Mantle ...
Stage I Margina...
Stage I Small L...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Waldenström Mac...
rituximab
cyclophosphamid...
filgrastim
yttrium Y 90 ib...
peripheral bloo...
18 Years - 70 YearsNational Cancer Institute (NCI)
Flavopiridol in Treating Patients With Recurrent Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma or Mantle Cell LymphomaNCT00003039
Lymphoma
alvocidib
18 Years - National Cancer Institute (NCI)
Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's LymphomaNCT00002649
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
aldesleukin
filgrastim
cyclophosphamid...
etoposide
radiation thera...
peripheral bloo...
bone marrow abl...
16 Years - 60 YearsNational Cancer Institute (NCI)
10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's LymphomaNCT00052442
Lymphoma
pralatrexate
18 Years - Spectrum Pharmaceuticals, Inc
SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's LymphomaNCT00101244
Adult Grade III...
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Splenic Margina...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Unspecified Adu...
Waldenström Mac...
ispinesib
laboratory biom...
pharmacological...
18 Years - National Cancer Institute (NCI)
Analysis of Dendritic Phenotype and Function of Patients Receiving VEGF-Trap on VGFT-ST-0202NCT00896662
Lymphoma
Solid Tumor
immunologic tec...
laboratory biom...
pharmacological...
18 Years - Vanderbilt-Ingram Cancer Center
Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's LymphomaNCT00005601
Lymphoma
rituximab
cisplatin
cytarabine
dexamethasone
sargramostim
18 Years - Alliance for Clinical Trials in Oncology
Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's LymphomaNCT00007852
Lymphoma
rituximab
carmustine
cytarabine
etoposide
melphalan
autologous hema...
19 Years - University of Nebraska
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic MalignancyNCT00891137
Leukemia
Lymphoma
Multiple Myelom...
Plasma Cell Neo...
Myelodysplastic...
human myeloid p...
12 Years - 65 YearsCellerant Therapeutics
Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's LymphomaNCT00004192
Lymphoma
Neutropenia
filgrastim
pegfilgrastim
cisplatin
cytarabine
etoposide
methylprednisol...
18 Years - 120 YearsUniversity of Nebraska
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell CancersNCT00003163
Lymphoma
Multiple Myelom...
filgrastim
sargramostim
cyclophosphamid...
melphalan
autologous bone...
peripheral bloo...
radiation thera...
18 Years - National Cancer Institute (NCI)
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney FunctionNCT00118170
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Refractory Mult...
Splenic Margina...
Stage II Multip...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Multi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Unspecified Adu...
Waldenström Mac...
sorafenib tosyl...
pharmacological...
18 Years - National Cancer Institute (NCI)
Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's LymphomaNCT00007865
Lymphoma
rituximab
carboplatin
etoposide
ifosfamide
19 Years - 120 YearsUniversity of Nebraska
Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular LymphomaNCT01722305
B-Cell Lymphoma...
Central Nervous...
Intraocular Lym...
Primary Diffuse...
Recurrent Adult...
Retinal Lymphom...
Dexamethasone
Laboratory Biom...
Pharmacological...
Pomalidomide
18 Years - Mayo Clinic
Flavopiridol in Treating Patients With Recurrent Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma or Mantle Cell LymphomaNCT00003039
Lymphoma
alvocidib
18 Years - National Cancer Institute (NCI)
Combination Chemotherapy Plus Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's LymphomaNCT00002697
Lymphoma
filgrastim
sargramostim
carboplatin
etoposide
ifosfamide
autologous bone...
bone marrow abl...
peripheral bloo...
radiation thera...
18 Years - 65 YearsMemorial Sloan Kettering Cancer Center
Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaNCT00244985
Lymphoma
rituximab
pegylated lipos...
18 Years - 120 YearsRoswell Park Cancer Institute
Study of Biomarkers Using Tissue Samples From Older Patients With Diffuse Large B-Cell Lymphoma Treated With Combination Chemotherapy With or Without Rituximab on Clinical Trial ECOG-E4494NCT00898157
Lymphoma
laboratory biom...
60 Years - 120 YearsEastern Cooperative Oncology Group
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic CancerNCT00003661
Graft Versus Ho...
Leukemia
Lymphoma
Myelodysplastic...
Neuroblastoma
anti-thymocyte ...
busulfan
cyclosporine
melphalan
methylprednisol...
umbilical cord ...
radiation thera...
- 54 YearsRoswell Park Cancer Institute
Denileukin Diftitox in Treating Patients With Non-Hodgkin's LymphomaNCT00026429
Leukemia
Lymphoma
denileukin dift...
18 Years - National Cancer Institute (NCI)
Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaNCT01812005
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Splenic Margina...
Waldenström Mac...
alisertib
rituximab
laboratory biom...
18 Years - Ohio State University Comprehensive Cancer Center
Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell TransplantationNCT00003143
Lymphoma
Amifostine
DHAP
18 Years - Jonsson Comprehensive Cancer Center
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's LymphomaNCT00082823
Cancer
ziv-aflibercept
18 Years - 120 YearsRegeneron Pharmaceuticals
Bryostatin 1 in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaNCT00002908
Leukemia
Lymphoma
bryostatin 1
vincristine sul...
18 Years - Barbara Ann Karmanos Cancer Institute
FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaNCT00383565
Recurrent Adult...
Recurrent Mantl...
romidepsin
18 Years - National Cancer Institute (NCI)
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's LymphomaNCT00003397
Lymphoma
filgrastim
rituximab
sargramostim
carmustine
cisplatin
cyclophosphamid...
dexamethasone
etoposide
gemcitabine hyd...
melphalan
paclitaxel
bone marrow abl...
peripheral bloo...
18 Years - 75 YearsUniversity of Maryland, Baltimore
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney FunctionNCT00118170
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Refractory Mult...
Splenic Margina...
Stage II Multip...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Multi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Unspecified Adu...
Waldenström Mac...
sorafenib tosyl...
pharmacological...
18 Years - National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Acute B-Lymphoblastic Leukemia or Non-Hodgkin's LymphomaNCT00002471
Leukemia
Lymphoma
asparaginase
cyclophosphamid...
cytarabine
daunorubicin hy...
dexamethasone
etoposide
leucovorin calc...
methotrexate
methylprednisol...
therapeutic hyd...
thiotepa
vincristine sul...
- Memorial Sloan Kettering Cancer Center
Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic SyndromeNCT00002989
Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
busulfan
cyclophosphamid...
idarubicin
melphalan
radiation thera...
16 Years - 60 YearsNational Cancer Institute (NCI)
Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaNCT00040950
Lymphoma
rituximab
agatolimod sodi...
18 Years - National Cancer Institute (NCI)
Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaNCT00062296
Leukemia
Lymphoma
rituximab
epirubicin hydr...
18 Years - Fox Chase Cancer Center
Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin LymphomaNCT00691652
Lymphoma
rituximab
clofarabine
DNA methylation...
gene expression...
microarray anal...
polymerase chai...
high performanc...
laboratory biom...
18 Years - 89 YearsOHSU Knight Cancer Institute
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin LymphomaNCT01045928
Adult Non-Hodgk...
Adult Grade III...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Cutaneous B-cel...
Extranodal Marg...
Nodal Marginal ...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Splenic Margina...
Stage I Adult B...
Stage I Adult D...
Stage I Adult D...
Stage I Adult D...
Stage I Adult I...
Stage I Adult L...
Stage I Grade 1...
Stage I Grade 2...
Stage I Grade 3...
Stage I Mantle ...
Stage I Margina...
Stage I Small L...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Waldenstrom Mac...
lenalidomide
rituximab
polymerase chai...
nucleic acid se...
polymorphism an...
flow cytometry
laboratory biom...
18 Years - Case Comprehensive Cancer Center
Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed or Progressive B-Cell Diffuse Large Cell LymphomaNCT00052923
Lymphoma
filgrastim
rituximab
carmustine
cyclophosphamid...
etoposide
peripheral bloo...
radiation thera...
18 Years - 70 YearsNational Cancer Institute (NCI)
Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic CancerNCT02240719
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Refractory Chro...
Multiple Myelom...
everolimus
bendamustine hy...
18 Years - University of California, Davis
Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's LymphomaNCT00110071
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Splenic Margina...
Waldenström Mac...
fludarabine pho...
peripheral bloo...
iodine I 131 to...
laboratory biom...
flow cytometry
polymerase chai...
60 Years - Fred Hutchinson Cancer Center
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic CancerNCT00010192
B-cell Adult Ac...
Extranodal Marg...
Nodal Marginal ...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Splenic Margina...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
rituximab
aldesleukin
laboratory biom...
pharmacological...
18 Years - National Cancer Institute (NCI)
Two Different Methods of Collecting Stem Cells For an Autologous Stem Cell Transplant in Treating Patients With Diffuse Large Cell LymphomaNCT00566228
Lymphoma
autologous hema...
leukapheresis
18 Years - 120 YearsMayo Clinic
Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin LymphomaNCT02281279
B-cell Adult Ac...
Extranodal Marg...
Intraocular Lym...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Refractory Hair...
Small Intestine...
Splenic Margina...
Testicular Lymp...
Waldenström Mac...
rituximab
lenalidomide
romidepsin
laboratory biom...
18 Years - Mayo Clinic
PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's LymphomaNCT00303953
Recurrent Adult...
Recurrent Adult...
belinostat
18 Years - National Cancer Institute (NCI)
PS-341 in Treating Patients With Advanced CancerNCT00006362
Leukemia
Lymphoma
Multiple Myelom...
Precancerous Co...
Unspecified Adu...
bortezomib
18 Years - Mayo Clinic
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By ChemotherapyNCT00003341
Anemia
Leukemia
Lymphoma
Multiple Myelom...
epoetin alfa
quality-of-life...
18 Years - Memorial Sloan Kettering Cancer Center
Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic CancerNCT00290641
Chronic Myelopr...
Leukemia
Lymphoma
Myelodysplastic...
filgrastim
graft-versus-tu...
cyclophosphamid...
cyclosporine
fludarabine pho...
mycophenolate m...
umbilical cord ...
radiation thera...
- 45 YearsMasonic Cancer Center, University of Minnesota
Etoposide in Treating Patients With Relapsed Non-Hodgkin's LymphomaNCT00002880
Lymphoma
Etoposide phosp...
- Alliance for Clinical Trials in Oncology
Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaNCT00040950
Lymphoma
rituximab
agatolimod sodi...
18 Years - National Cancer Institute (NCI)
Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic CancerNCT00782379
Leukemia
Lymphoma
Myelodysplastic...
busulfan
cyclophosphamid...
fludarabine pho...
mycophenolate m...
tacrolimus
allogeneic hema...
peripheral bloo...
18 Years - 60 YearsNorthside Hospital, Inc.
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic CancerNCT00003661
Graft Versus Ho...
Leukemia
Lymphoma
Myelodysplastic...
Neuroblastoma
anti-thymocyte ...
busulfan
cyclosporine
melphalan
methylprednisol...
umbilical cord ...
radiation thera...
- 54 YearsRoswell Park Cancer Institute
Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to TreatmentNCT00829205
Lymphoma
filgrastim
rituximab
Se-methyl-selen...
carboplatin
etoposide
ifosfamide
laboratory biom...
pharmacological...
18 Years - National Cancer Institute (NCI)
Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's LymphomaNCT00110071
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Splenic Margina...
Waldenström Mac...
fludarabine pho...
peripheral bloo...
iodine I 131 to...
laboratory biom...
flow cytometry
polymerase chai...
60 Years - Fred Hutchinson Cancer Center
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaNCT00073918
Anaplastic Larg...
Cutaneous B-cel...
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Splenic Margina...
Waldenström Mac...
cyclophosphamid...
etoposide
iodine I 131 to...
quality-of-life...
peripheral bloo...
18 Years - 60 YearsFred Hutchinson Cancer Center
Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHLNCT01686165
Anaplastic Larg...
Recurrent Adult...
Recurrent Mantl...
belinostat
rituximab
yttrium Y 90 ib...
18 Years - University of Arizona
Radiolabeled Monoclonal Antibody in Treating Patients With Previously Treated Large Cell LymphomaNCT00028613
Lymphoma
iodine I 131 mo...
18 Years - Case Comprehensive Cancer Center
Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's LymphomaNCT00006669
Lymphoma
rituximab
sargramostim
EPOCH regimen
cyclophosphamid...
doxorubicin hyd...
etoposide
prednisone
vincristine sul...
18 Years - 120 YearsMedstar Health Research Institute
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell NeoplasmsNCT00082784
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Refractory Plas...
Splenic Margina...
Waldenstrom Mac...
Bortezomib
Alvocidib Hydro...
Pharmacological...
18 Years - National Cancer Institute (NCI)
Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's LymphomaNCT00059904
Lymphoma
aldesleukin
rituximab
18 Years - National Cancer Institute (NCI)
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell CancersNCT00003163
Lymphoma
Multiple Myelom...
filgrastim
sargramostim
cyclophosphamid...
melphalan
autologous bone...
peripheral bloo...
radiation thera...
18 Years - National Cancer Institute (NCI)
Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's LymphomaNCT00004192
Lymphoma
Neutropenia
filgrastim
pegfilgrastim
cisplatin
cytarabine
etoposide
methylprednisol...
18 Years - 120 YearsUniversity of Nebraska
Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstrom's MacroglobulinemiaNCT00004107
Leukemia
Lymphoma
filgrastim
autologous bone...
peripheral bloo...
indium In 111 m...
yttrium Y 90 ep...
18 Years - 80 YearsGarden State Cancer Center at the Center for Molecular Medicine and Immunology
Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous LeukemiaNCT00275080
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Blastic Phase C...
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Secondary Acute...
Splenic Margina...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Unspecified Adu...
Untreated Adult...
Untreated Adult...
vorinostat
decitabine
18 Years - National Cancer Institute (NCI)
Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's LymphomaNCT00006669
Lymphoma
rituximab
sargramostim
EPOCH regimen
cyclophosphamid...
doxorubicin hyd...
etoposide
prednisone
vincristine sul...
18 Years - 120 YearsMedstar Health Research Institute
Tipifarnib in Treating Patients With Advanced Hematologic CancerNCT00005967
Chronic Myelopr...
Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
tipifarnib
18 Years - National Cancer Institute (NCI)
Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's LymphomaNCT00086944
Recurrent Adult...
Recurrent Grade...
Recurrent Mantl...
oblimersen sodi...
rituximab
ifosfamide
carboplatin
etoposide
filgrastim
pegfilgrastim
laboratory biom...
18 Years - National Cancer Institute (NCI)
Etoposide in Treating Patients With Relapsed Non-Hodgkin's LymphomaNCT00002880
Lymphoma
Etoposide phosp...
- Alliance for Clinical Trials in Oncology
Denileukin Diftitox in Treating Patients With Non-Hodgkin's LymphomaNCT00026429
Leukemia
Lymphoma
denileukin dift...
18 Years - National Cancer Institute (NCI)
Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's LymphomaNCT00058019
Anaplastic Larg...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Mantl...
ixabepilone
18 Years - National Cancer Institute (NCI)
Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's LymphomaNCT00387959
Leukemia
Lymphoma
filgrastim
rituximab
cyclophosphamid...
cyclosporine
fludarabine pho...
mycophenolate m...
allogeneic hema...
umbilical cord ...
total-body irra...
18 Years - 70 YearsMemorial Sloan Kettering Cancer Center
Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to TreatmentNCT00829205
Lymphoma
filgrastim
rituximab
Se-methyl-selen...
carboplatin
etoposide
ifosfamide
laboratory biom...
pharmacological...
18 Years - National Cancer Institute (NCI)
Bryostatin-1 in Treating Patients With Recurrent Non-Hodgkin's LymphomaNCT00002725
Lymphoma
bryostatin 1
chemotherapy
- National Cancer Institute (NCI)
Long-Term Effects of Iodine I Tositumomab and Autologous Bone Marrow or Stem Cell Transplantation in Patients With Relapsed or Refractory Non-Hodgkin's LymphomaNCT00098566
Lymphoma
Quality of Life
18 Years - 120 YearsFred Hutchinson Cancer Center
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: